Skip to main content
Erschienen in: Current Neurology and Neuroscience Reports 3/2010

01.05.2010

The Role of Glucocerebrosidase Mutations in Parkinson Disease and Lewy Body Disorders

verfasst von: Arash Velayati, W. Haung Yu, Ellen Sidransky

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Mutations in the gene encoding glucocerebrosidase (GBA), the enzyme deficient in the lysosomal storage disorder Gaucher disease, are associated with the development of Parkinson disease and other Lewy body disorders. In fact, GBA variants are currently the most common genetic risk factor associated with parkinsonism, and identified subjects with Parkinson disease are more than five times more likely to carry mutations in GBA. The mechanisms underlying this association are not known, but proposed theories include enhanced protein aggregation, alterations in lipid levels, and autophagy-lysosomal dysfunction promoting the retention of undegraded proteins. We review the genetic studies linking GBA to parkinsonism, as well as several of the mechanisms postulated to explain the association of GBA mutations and the synucleinopathies, which demonstrate how studies of a rare mendelian disease may provide insights into our understanding of a common complex disorder.
Literatur
1.
Zurück zum Zitat Beutler E: Gaucher disease: new molecular approaches to diagnosis and treatment. Science 1992, 256:794–799.CrossRefPubMed Beutler E: Gaucher disease: new molecular approaches to diagnosis and treatment. Science 1992, 256:794–799.CrossRefPubMed
2.
Zurück zum Zitat Horowitz M, Wilder S, Horowitz Z, et al.: The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics 1989, 4:87–96.CrossRefPubMed Horowitz M, Wilder S, Horowitz Z, et al.: The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics 1989, 4:87–96.CrossRefPubMed
3.
Zurück zum Zitat Sorge J, West C, Westwood B, Beutler E: Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA. Proc Nat Acad Sci U S A 1985, 82:7289–7293.CrossRef Sorge J, West C, Westwood B, Beutler E: Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA. Proc Nat Acad Sci U S A 1985, 82:7289–7293.CrossRef
4.
Zurück zum Zitat Barneveld RA, Keijzer W, Tegelaers FP, et al.: Assignment of the gene coding for human beta-glucocerebrosidase to the region q21–q31 of chromosome 1 using monoclonal antibodies. Hum Genet 1993, 64:227–231.CrossRef Barneveld RA, Keijzer W, Tegelaers FP, et al.: Assignment of the gene coding for human beta-glucocerebrosidase to the region q21–q31 of chromosome 1 using monoclonal antibodies. Hum Genet 1993, 64:227–231.CrossRef
5.
Zurück zum Zitat Winfield SL, Tayebi N, Martin BM, et al.: Identification of three additional genes contiguous to the glucocerebrosidase locus on chromosome 1q21: implications for Gaucher disease. Genome Res 1997, 7:1020–1026.PubMed Winfield SL, Tayebi N, Martin BM, et al.: Identification of three additional genes contiguous to the glucocerebrosidase locus on chromosome 1q21: implications for Gaucher disease. Genome Res 1997, 7:1020–1026.PubMed
6.
Zurück zum Zitat Sorge J, Gross E, West C, Beutler E: High level transcription of the glucocerebrosidase pseudogene in normal subjects and patients with Gaucher disease. J Clin Invest 1990, 86:1137–1141.CrossRefPubMed Sorge J, Gross E, West C, Beutler E: High level transcription of the glucocerebrosidase pseudogene in normal subjects and patients with Gaucher disease. J Clin Invest 1990, 86:1137–1141.CrossRefPubMed
7.
Zurück zum Zitat Gaucher PCE: On primary epithelioma of the spleen: idiopathic hypertrophy of the spleen without leukemia. Thesis, Doctor of Medicine. Paris: Octave Doin; 1882. Gaucher PCE: On primary epithelioma of the spleen: idiopathic hypertrophy of the spleen without leukemia. Thesis, Doctor of Medicine. Paris: Octave Doin; 1882.
8.
Zurück zum Zitat • Hruska KS, LaMarca ME, Scott CR, Sidransky E: Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 2008, 29:567–583. This work provides a comprehensive review of the structure of GBA and the mutations identified. • Hruska KS, LaMarca ME, Scott CR, Sidransky E: Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 2008, 29:567–583. This work provides a comprehensive review of the structure of GBA and the mutations identified.
9.
Zurück zum Zitat Koprivica V, Stone DL, Park JK, et al.: Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet 2000, 66:1777–1786.CrossRefPubMed Koprivica V, Stone DL, Park JK, et al.: Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet 2000, 66:1777–1786.CrossRefPubMed
10.
Zurück zum Zitat Goker-Alpan O, Hruska KS, Orvisky E, et al.: Divergent phenotypes in Gaucher disease implicate the role of modifiers. J Med Genet 2005, 42:e37.CrossRefPubMed Goker-Alpan O, Hruska KS, Orvisky E, et al.: Divergent phenotypes in Gaucher disease implicate the role of modifiers. J Med Genet 2005, 42:e37.CrossRefPubMed
11.
Zurück zum Zitat Neudorfer O, Giladi N, Elstein D, et al.: Occurrence of Parkinson’s syndrome in type I Gaucher disease. QJM 1996, 89:691–694.PubMed Neudorfer O, Giladi N, Elstein D, et al.: Occurrence of Parkinson’s syndrome in type I Gaucher disease. QJM 1996, 89:691–694.PubMed
12.
Zurück zum Zitat Machaczka M, Rucinska M, Skotnicki AB, Jurczak W: Parkinson’s syndrome preceding clinical manifestation of Gaucher’s disease. Am J Hematol 1999, 61:216–217.CrossRefPubMed Machaczka M, Rucinska M, Skotnicki AB, Jurczak W: Parkinson’s syndrome preceding clinical manifestation of Gaucher’s disease. Am J Hematol 1999, 61:216–217.CrossRefPubMed
13.
Zurück zum Zitat Várkonyi J, Rosenbaum H, Baumann N, et al.: Gaucher disease associated with parkinsonism: four further case reports. Am J Med Genet A 2003, 116A:348–351.CrossRefPubMed Várkonyi J, Rosenbaum H, Baumann N, et al.: Gaucher disease associated with parkinsonism: four further case reports. Am J Med Genet A 2003, 116A:348–351.CrossRefPubMed
14.
Zurück zum Zitat Goker-Alpan O, Schiffmann R, LaMarca ME, et al.: Parkinsonism among Gaucher disease carriers. J Med Genet 2004, 41:937–940.CrossRefPubMed Goker-Alpan O, Schiffmann R, LaMarca ME, et al.: Parkinsonism among Gaucher disease carriers. J Med Genet 2004, 41:937–940.CrossRefPubMed
15.
Zurück zum Zitat Halperin A, Elstein D, Zimran A: Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol Dis 2006, 36:426–428.CrossRefPubMed Halperin A, Elstein D, Zimran A: Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol Dis 2006, 36:426–428.CrossRefPubMed
16.
Zurück zum Zitat Goker-Alpan O, Giasson BI, Eblan MJ, et al.: Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 2006, 67:908–910.CrossRefPubMed Goker-Alpan O, Giasson BI, Eblan MJ, et al.: Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 2006, 67:908–910.CrossRefPubMed
17.
Zurück zum Zitat Tayebi N, Callahan M, Madike V, et al.: Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 2001, 73:313–321.CrossRefPubMed Tayebi N, Callahan M, Madike V, et al.: Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 2001, 73:313–321.CrossRefPubMed
18.
Zurück zum Zitat Tayebi N, Walker J, Stubblefield B, et al.: Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 2003, 79:104–109.CrossRefPubMed Tayebi N, Walker J, Stubblefield B, et al.: Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 2003, 79:104–109.CrossRefPubMed
19.
Zurück zum Zitat Lwin A, Orvisky E, Goker-Alpan O, et al.: Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 2004, 81(1):70–73.CrossRefPubMed Lwin A, Orvisky E, Goker-Alpan O, et al.: Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 2004, 81(1):70–73.CrossRefPubMed
20.
Zurück zum Zitat Park JK, Tayebi N, Stubblefield BK, et al.: The E326K mutation and Gaucher disease: mutation or polymorphism? Clin Genet 2002, 61(1):32–34.CrossRefPubMed Park JK, Tayebi N, Stubblefield BK, et al.: The E326K mutation and Gaucher disease: mutation or polymorphism? Clin Genet 2002, 61(1):32–34.CrossRefPubMed
21.
Zurück zum Zitat Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R: Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med 2004, 351(19):1972–1977.CrossRefPubMed Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R: Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med 2004, 351(19):1972–1977.CrossRefPubMed
22.
Zurück zum Zitat Sato C, Morgan A, Lang AE, et al.: Analysis of the glucocerebrosidase gene in Parkinson’s disease. Mov Disord 2005, 20(3):367–370.CrossRefPubMed Sato C, Morgan A, Lang AE, et al.: Analysis of the glucocerebrosidase gene in Parkinson’s disease. Mov Disord 2005, 20(3):367–370.CrossRefPubMed
23.
Zurück zum Zitat Toft M, Pielsticker L, Ross OA, et al.: Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population. Neurology 2006, 66(3):415–417.CrossRefPubMed Toft M, Pielsticker L, Ross OA, et al.: Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population. Neurology 2006, 66(3):415–417.CrossRefPubMed
24.
Zurück zum Zitat Eblan MJ, Nguyen J, Ziegler SG, et al.: Glucocerebrosidase mutations are also found in subjects with early-onset parkinsonism from Venezuela. Mov Disord 2006, 21(2):282–283.CrossRefPubMed Eblan MJ, Nguyen J, Ziegler SG, et al.: Glucocerebrosidase mutations are also found in subjects with early-onset parkinsonism from Venezuela. Mov Disord 2006, 21(2):282–283.CrossRefPubMed
25.
Zurück zum Zitat Tan EK, Tong J, Fook-Chong S, et al.: Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients. Arch Neurol 2007, 64(7):1056–1058.CrossRefPubMed Tan EK, Tong J, Fook-Chong S, et al.: Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients. Arch Neurol 2007, 64(7):1056–1058.CrossRefPubMed
26.
Zurück zum Zitat Ziegler SG, Eblan MJ, Gutti U, et al.: Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol Genet Metab 2007, 91(2):195–200.CrossRefPubMed Ziegler SG, Eblan MJ, Gutti U, et al.: Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol Genet Metab 2007, 91(2):195–200.CrossRefPubMed
27.
Zurück zum Zitat Clark LN, Ross BM, Wang Y, et al.: Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 2007, 69(12):1270–1277.CrossRefPubMed Clark LN, Ross BM, Wang Y, et al.: Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 2007, 69(12):1270–1277.CrossRefPubMed
28.
Zurück zum Zitat Wu YR, Chen CM, Chao CY, et al.: Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. J Neurol Neurosurg Psychiatry 2007, 78(9):977–979.CrossRefPubMed Wu YR, Chen CM, Chao CY, et al.: Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. J Neurol Neurosurg Psychiatry 2007, 78(9):977–979.CrossRefPubMed
29.
Zurück zum Zitat • Gan-Or Z, Giladi N, Rozovski U, et al.: Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 2008, 70(24):2277–2283. This study included the largest cohort of Ashkenazi Jewish subjects with parkinsonism screened for GBA mutations. • Gan-Or Z, Giladi N, Rozovski U, et al.: Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 2008, 70(24):2277–2283. This study included the largest cohort of Ashkenazi Jewish subjects with parkinsonism screened for GBA mutations.
30.
Zurück zum Zitat Spitz M, Rozenberg R, Pereira Lda V, Reis Barbosa E: Association between Parkinson’s disease and glucocerebrosidase mutations in Brazil. Parkinsonism Relat Disord 2008, 14(1):58–62.CrossRefPubMed Spitz M, Rozenberg R, Pereira Lda V, Reis Barbosa E: Association between Parkinson’s disease and glucocerebrosidase mutations in Brazil. Parkinsonism Relat Disord 2008, 14(1):58–62.CrossRefPubMed
31.
Zurück zum Zitat • Neumann J, Bras J, Deas E, et al.: Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. Brain 2009, 132(Pt 7):1783–1794. The authors sequenced the GBA gene in a large series of brains from subjects with PD as well as controls. They identified mutations in 4.2% of patients versus 1.2% of controls. • Neumann J, Bras J, Deas E, et al.: Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. Brain 2009, 132(Pt 7):1783–1794. The authors sequenced the GBA gene in a large series of brains from subjects with PD as well as controls. They identified mutations in 4.2% of patients versus 1.2% of controls.
32.
Zurück zum Zitat Nichols WC, Pankratz N, Marek DK, et al.; Parkinson Study Group-PROGENI Investigators: Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 2009, 72(4):310–316.CrossRefPubMed Nichols WC, Pankratz N, Marek DK, et al.; Parkinson Study Group-PROGENI Investigators: Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 2009, 72(4):310–316.CrossRefPubMed
33.
Zurück zum Zitat Kalinderi K, Bostantjopoulou S, Paisan-Ruiz C, et al.: Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. Neurosci Lett 2009, 452(2):87–89.CrossRefPubMed Kalinderi K, Bostantjopoulou S, Paisan-Ruiz C, et al.: Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. Neurosci Lett 2009, 452(2):87–89.CrossRefPubMed
34.
Zurück zum Zitat • Mitsui J, Mizuta I, Toyoda A, et al.: Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol 2009, 66(5):571–576. This study, conducted in Japan, demonstrates that in this cohort, GBA mutations are encountered frequently in subjects with PD. The spectrum of mutations, however, differed from cohorts of other ethnicities. • Mitsui J, Mizuta I, Toyoda A, et al.: Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol 2009, 66(5):571–576. This study, conducted in Japan, demonstrates that in this cohort, GBA mutations are encountered frequently in subjects with PD. The spectrum of mutations, however, differed from cohorts of other ethnicities.
35.
Zurück zum Zitat Bras J, Paisan-Ruiz C, Guerreiro R, et al.: Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. Neurobiol Aging 2009, 30(9):1515–1517.CrossRefPubMed Bras J, Paisan-Ruiz C, Guerreiro R, et al.: Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. Neurobiol Aging 2009, 30(9):1515–1517.CrossRefPubMed
36.
Zurück zum Zitat •• Sidransky E, Nalls MA, Aasly JO, et al.: Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med 2009, 361:1651–1661. This multicenter international collaborative study combined the results from 16 different centers in four continents. Studying more than 5000 patients and an equal number of controls, the authors demonstrated that the odds ratio for carrying a GBA mutation in patients with PD was greater than 5. •• Sidransky E, Nalls MA, Aasly JO, et al.: Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med 2009, 361:1651–1661. This multicenter international collaborative study combined the results from 16 different centers in four continents. Studying more than 5000 patients and an equal number of controls, the authors demonstrated that the odds ratio for carrying a GBA mutation in patients with PD was greater than 5.
37.
Zurück zum Zitat Gutti U, Fung HC, Hruska KS, et al.: The need for appropriate genotyping strategies for glucocerebrosidase mutations in cohorts with Parkinson disease. Arch Neurol 2008, 65:850–851.CrossRefPubMed Gutti U, Fung HC, Hruska KS, et al.: The need for appropriate genotyping strategies for glucocerebrosidase mutations in cohorts with Parkinson disease. Arch Neurol 2008, 65:850–851.CrossRefPubMed
38.
Zurück zum Zitat Wan L, Hsu CM, Tsai CH, et al.: Mutation analysis of Gaucher disease patients in Taiwan: high prevalence of the RecNciI and L444P mutations. Blood Cells Mol Dis 2006, 36:422–425.CrossRefPubMed Wan L, Hsu CM, Tsai CH, et al.: Mutation analysis of Gaucher disease patients in Taiwan: high prevalence of the RecNciI and L444P mutations. Blood Cells Mol Dis 2006, 36:422–425.CrossRefPubMed
39.
Zurück zum Zitat McKeith IG, Dickson DW, Lowe J, et al.: Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65:1863–1872.CrossRefPubMed McKeith IG, Dickson DW, Lowe J, et al.: Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65:1863–1872.CrossRefPubMed
40.
Zurück zum Zitat Wenning GK, Jellinger KA: The role of alpha-synuclein in the pathogenesis of multiple system atrophy. Acta Neuropathol 2005, 109:129–140.CrossRefPubMed Wenning GK, Jellinger KA: The role of alpha-synuclein in the pathogenesis of multiple system atrophy. Acta Neuropathol 2005, 109:129–140.CrossRefPubMed
41.
Zurück zum Zitat Mata IF, Samii A, Schneer SH, et al.: Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol 2008, 65:379–382.CrossRefPubMed Mata IF, Samii A, Schneer SH, et al.: Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol 2008, 65:379–382.CrossRefPubMed
42.
Zurück zum Zitat Farrer MJ, Williams LN, Algom AA, et al.: Glucosidase-beta variations and Lewy body disorders. Parkinsonism Relat Disord 2009, 15:414–416.CrossRefPubMed Farrer MJ, Williams LN, Algom AA, et al.: Glucosidase-beta variations and Lewy body disorders. Parkinsonism Relat Disord 2009, 15:414–416.CrossRefPubMed
43.
Zurück zum Zitat Clark LN, Kartsaklis LA, Wolf Gilbert R, et al.: Association of glucocerebrosidase mutations with dementia with lewy bodies. Arch Neurol 2009, 66:578–583.CrossRefPubMed Clark LN, Kartsaklis LA, Wolf Gilbert R, et al.: Association of glucocerebrosidase mutations with dementia with lewy bodies. Arch Neurol 2009, 66:578–583.CrossRefPubMed
44.
Zurück zum Zitat Segarane B, Li A, Paudel R, et al.: Glucocerebrosidase mutations in 108 neuropathologically confirmed cases of multiple system atrophy. Neurology 2009, 72:1185–1186.CrossRefPubMed Segarane B, Li A, Paudel R, et al.: Glucocerebrosidase mutations in 108 neuropathologically confirmed cases of multiple system atrophy. Neurology 2009, 72:1185–1186.CrossRefPubMed
45.
Zurück zum Zitat Jamrozik Z, Lugowska A, Slawek J, Kwiecinski H: Glucocerebrosidase mutations p.L444P and p.N370S are not associated with multisystem atrophy, progressive supranuclear palsy and corticobasal degeneration in Polish patients. J Neurol 2009 Nov 1 (Epub ahead of print). Jamrozik Z, Lugowska A, Slawek J, Kwiecinski H: Glucocerebrosidase mutations p.L444P and p.N370S are not associated with multisystem atrophy, progressive supranuclear palsy and corticobasal degeneration in Polish patients. J Neurol 2009 Nov 1 (Epub ahead of print).
46.
Zurück zum Zitat Bembi B, Zambito Marsala S, Sidransky E, et al.: Gaucher’s disease with Parkinson’s disease: clinical and pathological aspects. Neurology 2003, 61:99–101.PubMed Bembi B, Zambito Marsala S, Sidransky E, et al.: Gaucher’s disease with Parkinson’s disease: clinical and pathological aspects. Neurology 2003, 61:99–101.PubMed
47.
Zurück zum Zitat Wong K, Sidransky E, Verma A, et al.: Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 2004, 82:192–207.CrossRefPubMed Wong K, Sidransky E, Verma A, et al.: Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 2004, 82:192–207.CrossRefPubMed
48.
Zurück zum Zitat Kono S, Shirakawa K, Ouchi Y, et al.: Dopaminergic neuronal dysfunction associated with parkinsonism in both a Gaucher disease patient and a carrier. J Neurol Sci 2007, 252:181–184.CrossRefPubMed Kono S, Shirakawa K, Ouchi Y, et al.: Dopaminergic neuronal dysfunction associated with parkinsonism in both a Gaucher disease patient and a carrier. J Neurol Sci 2007, 252:181–184.CrossRefPubMed
49.
Zurück zum Zitat Goker-Alpan O, Lopez G, Vithayathil J, et al.: The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 2008, 65:1353–1357.CrossRefPubMed Goker-Alpan O, Lopez G, Vithayathil J, et al.: The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 2008, 65:1353–1357.CrossRefPubMed
50.
Zurück zum Zitat Gan-Or Z, Giladi N, Orr-Urtreger A: Differential phenotype in Parkinson’s disease patients with severe versus mild GBA mutations. Brain 2009, 132:e125.CrossRefPubMed Gan-Or Z, Giladi N, Orr-Urtreger A: Differential phenotype in Parkinson’s disease patients with severe versus mild GBA mutations. Brain 2009, 132:e125.CrossRefPubMed
51.
Zurück zum Zitat Hardy J, Lewis P, Revesz T, et al.: The genetics of Parkinson’s syndromes: a critical review. Curr Opin Genet Dev 2009, 19:254–265.CrossRefPubMed Hardy J, Lewis P, Revesz T, et al.: The genetics of Parkinson’s syndromes: a critical review. Curr Opin Genet Dev 2009, 19:254–265.CrossRefPubMed
52.
Zurück zum Zitat Bras J, Singleton A, Cookson MR, Hardy J: Emerging pathways in genetic Parkinson’s disease: potential role of ceramide metabolism in Lewy body disease. FEBS J 2008, 275:5767–5773.CrossRefPubMed Bras J, Singleton A, Cookson MR, Hardy J: Emerging pathways in genetic Parkinson’s disease: potential role of ceramide metabolism in Lewy body disease. FEBS J 2008, 275:5767–5773.CrossRefPubMed
53.
Zurück zum Zitat Conradi NG, Sourander P, Nilsson O, et al.: Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies. Acta Neuropathol 1984, 65:99–109.CrossRefPubMed Conradi NG, Sourander P, Nilsson O, et al.: Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies. Acta Neuropathol 1984, 65:99–109.CrossRefPubMed
54.
Zurück zum Zitat Jo E, McLaurin J, Yip CM, et al.: alpha-Synuclein membrane interactions and lipid specificity. J Biol Chem 2000, 275:34328–34334.CrossRefPubMed Jo E, McLaurin J, Yip CM, et al.: alpha-Synuclein membrane interactions and lipid specificity. J Biol Chem 2000, 275:34328–34334.CrossRefPubMed
55.
Zurück zum Zitat Schlossmacher MG, Cullen V, Müthing J: The glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med 2005, 352:728–731.CrossRefPubMed Schlossmacher MG, Cullen V, Müthing J: The glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med 2005, 352:728–731.CrossRefPubMed
56.
Zurück zum Zitat Simons K, Gruenberg J: Jamming the endosomal system: lipid rafts and lysosomal storage diseases. Trends Cell Biol 2000, 10:459–462.CrossRefPubMed Simons K, Gruenberg J: Jamming the endosomal system: lipid rafts and lysosomal storage diseases. Trends Cell Biol 2000, 10:459–462.CrossRefPubMed
57.
Zurück zum Zitat Martinez Z, Zhu M, Han S, Fink AL: GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry 2007, 46:1868–1877.CrossRefPubMed Martinez Z, Zhu M, Han S, Fink AL: GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry 2007, 46:1868–1877.CrossRefPubMed
58.
Zurück zum Zitat Sharon R, Bar-Joseph I, Frosch MP, et al.: The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson’s disease. Neuron 2003, 37:583–595.CrossRefPubMed Sharon R, Bar-Joseph I, Frosch MP, et al.: The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson’s disease. Neuron 2003, 37:583–595.CrossRefPubMed
59.
Zurück zum Zitat Manning-Boğ AB, Schüle B, Langston JW: Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology 2009, 30(6):1127–1132.CrossRefPubMed Manning-Boğ AB, Schüle B, Langston JW: Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology 2009, 30(6):1127–1132.CrossRefPubMed
60.
Zurück zum Zitat Sawkar AR, Adamski-Werner SL, Cheng WC, et al.: Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem Biol 2005, 12:1235–1244.CrossRefPubMed Sawkar AR, Adamski-Werner SL, Cheng WC, et al.: Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem Biol 2005, 12:1235–1244.CrossRefPubMed
61.
Zurück zum Zitat de Duve C: From cytases to lysosomes. Fed Proc 1964, 23:1045–1049. de Duve C: From cytases to lysosomes. Fed Proc 1964, 23:1045–1049.
62.
Zurück zum Zitat Essner E, Novikoff AB: Localization of acid phosphatase activity in hepatic lysosomes by means of electron microscopy. J Biophys Biochem Cytol 1961, 9:773–784.CrossRefPubMed Essner E, Novikoff AB: Localization of acid phosphatase activity in hepatic lysosomes by means of electron microscopy. J Biophys Biochem Cytol 1961, 9:773–784.CrossRefPubMed
63.
Zurück zum Zitat Ramirez A, Heimbach A, Grundemann J, et al.: Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006, 38:1184–1191.CrossRefPubMed Ramirez A, Heimbach A, Grundemann J, et al.: Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006, 38:1184–1191.CrossRefPubMed
64.
Zurück zum Zitat Di Fonzo A, Chien HF, Socal M, et al.: ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 2007, 68:1557–1562.CrossRefPubMed Di Fonzo A, Chien HF, Socal M, et al.: ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 2007, 68:1557–1562.CrossRefPubMed
65.
Zurück zum Zitat Cuervo AM, Stefanis L, Fredenburg R, et al.: Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292–1295.CrossRefPubMed Cuervo AM, Stefanis L, Fredenburg R, et al.: Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292–1295.CrossRefPubMed
66.
Zurück zum Zitat Martinez-Vicente M, Talloczy Z, Kaushik S, et al.: Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 2008, 118:777–788.PubMed Martinez-Vicente M, Talloczy Z, Kaushik S, et al.: Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 2008, 118:777–788.PubMed
67.
Zurück zum Zitat Klionsky DJ, Emr SD: Autophagy as a regulated pathway of cellular degradation. Science 2000, 290:1717–1721.CrossRefPubMed Klionsky DJ, Emr SD: Autophagy as a regulated pathway of cellular degradation. Science 2000, 290:1717–1721.CrossRefPubMed
68.
Zurück zum Zitat Sou YS, Tanida I, Komatsu M, et al.: Phosphatidylserine in addition to phosphatidylethanolamine is an in vitro target of the mammalian Atg8 modifiers, LC3, GABARAP, and GATE-16. J Biol Chem 2006, 281:3017–3024.CrossRefPubMed Sou YS, Tanida I, Komatsu M, et al.: Phosphatidylserine in addition to phosphatidylethanolamine is an in vitro target of the mammalian Atg8 modifiers, LC3, GABARAP, and GATE-16. J Biol Chem 2006, 281:3017–3024.CrossRefPubMed
69.
Zurück zum Zitat Webb JL, Ravikumar B, Atkins J, et al.: Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 2003, 278:25009–25013.CrossRefPubMed Webb JL, Ravikumar B, Atkins J, et al.: Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 2003, 278:25009–25013.CrossRefPubMed
70.
Zurück zum Zitat Yu WH, Dorado B, Figueroa HY, et al.: Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am J Pathol 2009, 175:736–747.CrossRefPubMed Yu WH, Dorado B, Figueroa HY, et al.: Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am J Pathol 2009, 175:736–747.CrossRefPubMed
71.
Zurück zum Zitat Spencer B, Potkar R, Trejo M, et al.: Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson’s and Lewy body diseases. J Neurosci 2009, 29:13578–13588.CrossRefPubMed Spencer B, Potkar R, Trejo M, et al.: Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson’s and Lewy body diseases. J Neurosci 2009, 29:13578–13588.CrossRefPubMed
72.
Zurück zum Zitat Hara T, Nakamura K, Matsui M, et al.: Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441:885–889.CrossRefPubMed Hara T, Nakamura K, Matsui M, et al.: Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441:885–889.CrossRefPubMed
73.
Zurück zum Zitat Komatsu M, Waguri S, Chiba T, et al.: Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441:880–884.CrossRefPubMed Komatsu M, Waguri S, Chiba T, et al.: Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441:880–884.CrossRefPubMed
74.
Zurück zum Zitat Singh R, Kaushik S, Wang Y, et al.: Autophagy regulates lipid metabolism. Nature 2009, 458:1131–1135.CrossRefPubMed Singh R, Kaushik S, Wang Y, et al.: Autophagy regulates lipid metabolism. Nature 2009, 458:1131–1135.CrossRefPubMed
75.
Zurück zum Zitat Scarlatti F, Bauvy C, Ventruti A, et al.: Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1. J Biol Chem 2004, 279:18384–18391.CrossRefPubMed Scarlatti F, Bauvy C, Ventruti A, et al.: Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1. J Biol Chem 2004, 279:18384–18391.CrossRefPubMed
76.
Zurück zum Zitat Dawson TM: Parkin and defective ubiquitination in Parkinson’s disease. J Neural Transm Suppl 2006, 70:209–213.CrossRefPubMed Dawson TM: Parkin and defective ubiquitination in Parkinson’s disease. J Neural Transm Suppl 2006, 70:209–213.CrossRefPubMed
77.
Zurück zum Zitat Ron I, Horowitz M: ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum Mol Genet 2005, 14:2387–2398.CrossRefPubMed Ron I, Horowitz M: ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum Mol Genet 2005, 14:2387–2398.CrossRefPubMed
78.
Zurück zum Zitat Horowitz M, Ron I: Interaction between parkin and glucocerebrosidase: a possible link between Parkinson disease and Gaucher disease. Mol Genet Metab 2009, 96:S27.CrossRef Horowitz M, Ron I: Interaction between parkin and glucocerebrosidase: a possible link between Parkinson disease and Gaucher disease. Mol Genet Metab 2009, 96:S27.CrossRef
79.
Zurück zum Zitat Clark LN, Nicolai A, Afridi S, et al.: Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson’s disease in subjects of Jewish ethnicity. Mov Disord 2005, 20:100–103.CrossRefPubMed Clark LN, Nicolai A, Afridi S, et al.: Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson’s disease in subjects of Jewish ethnicity. Mov Disord 2005, 20:100–103.CrossRefPubMed
80.
Zurück zum Zitat De Marco EV, Annesi G, Tarantino P, et al.: Glucocerebrosidase gene mutations are associated with Parkinson’s disease in southern Italy. Mov Disord 2008, 23:460–463.CrossRefPubMed De Marco EV, Annesi G, Tarantino P, et al.: Glucocerebrosidase gene mutations are associated with Parkinson’s disease in southern Italy. Mov Disord 2008, 23:460–463.CrossRefPubMed
Metadaten
Titel
The Role of Glucocerebrosidase Mutations in Parkinson Disease and Lewy Body Disorders
verfasst von
Arash Velayati
W. Haung Yu
Ellen Sidransky
Publikationsdatum
01.05.2010
Verlag
Current Science Inc.
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 3/2010
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-010-0102-x

Weitere Artikel der Ausgabe 3/2010

Current Neurology and Neuroscience Reports 3/2010 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.